Publications by authors named "A Tosetto"
Article Synopsis
- The Phase 3 XTEND-1 trial demonstrated that efanesoctocog alfa provides better bleed protection than standard factor VIII (FVIII) replacement therapies for patients with severe hemophilia A.
- A systematic literature review was conducted to compare bleeding outcomes between efanesoctocog alfa and different types of FVIII therapies, using statistical methods to analyze annualized bleeding rates (ABRs).
- Results showed that efanesoctocog alfa was linked to significantly fewer annual bleeds, averaging 2.2 fewer versus extended half-life therapies and 3.6 fewer versus standard therapies.
Article Synopsis
- Frailty affects how well anticoagulant therapy works for patients with atrial fibrillation (AF), and the age-weighted Charlson comorbidity index may help assess risks in these patients treated with direct oral anticoagulants (DOACs).
- In a sub-analysis of the MAS trial, researchers compared dosing based on the Charlson index with standard criteria and examined its impact on adverse events.
- While the Charlson index influenced dosing decisions, it did not improve the prediction of adverse events in AF patients, indicating that the standard approach remains valid.
Introduction: Mechanical heart valve (MHV) replacement requires long-life anticoagulation due to the risk of Prosthetic Valve Dysfunction (PVD) and cardioembolism.
Methods: We report data from a prospective observational study conducted on MHV patients in the Khartoum Salam Centre for Cardiac Surgery built by 'Emergency,' an Italian Non-Governmental Organization, to evaluate the occurrence of PVD and associated risk factors.
Results: We prospectively followed 3647 patients, and 38 patients (rate 1.
Background: The MAS study (Blood Advances 2024) showed that a high proportion of Italian AF patients treated with direct oral anticoagulants (DOACs) receive reduced doses. This sub-analysis of MAS data aimed to analyze the effects of reduced (appropriate or not)- or standard-dose use on DOAC activity assessed at baseline and the occurrence of thrombotic or bleeding complications during follow-up.
Methods: The MAS study design, the methods for DOAC measurement, the results, and the adverse events during follow-up, are described in detail elsewhere.
Article Synopsis
- - Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C), specifically Fanhdi® and Alphanate®, are commonly used to treat von Willebrand disease (VWD) in Italy, and a study evaluated their real-world effectiveness and safety.
- - The retrospective study involved 57 patients with different types of VWD, treating various bleeding episodes, surgical procedures, and long-term prophylaxis over a period from 2007 to 2019.
- - Results showed that pd-VWF/FVIII-C had excellent or good efficacy in 85% of bleeding episodes, 98% of surgeries, and 100% of long-term prophylaxis cases, with no serious safety concerns reported. *